IL231829D0 - Etanercept formulations stabilized with combinations of sugars and polyols - Google Patents

Etanercept formulations stabilized with combinations of sugars and polyols

Info

Publication number
IL231829D0
IL231829D0 IL231829A IL23182914A IL231829D0 IL 231829 D0 IL231829 D0 IL 231829D0 IL 231829 A IL231829 A IL 231829A IL 23182914 A IL23182914 A IL 23182914A IL 231829 D0 IL231829 D0 IL 231829D0
Authority
IL
Israel
Prior art keywords
polyols
sugars
combinations
etanercept formulations
formulations stabilized
Prior art date
Application number
IL231829A
Other languages
Hebrew (he)
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161548518P priority Critical
Priority to US201261669480P priority
Priority to PCT/US2012/060748 priority patent/WO2013059412A1/en
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of IL231829D0 publication Critical patent/IL231829D0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
IL231829A 2011-10-18 2014-03-31 Etanercept formulations stabilized with combinations of sugars and polyols IL231829D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201161548518P true 2011-10-18 2011-10-18
US201261669480P true 2012-07-09 2012-07-09
PCT/US2012/060748 WO2013059412A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols

Publications (1)

Publication Number Publication Date
IL231829D0 true IL231829D0 (en) 2014-05-28

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
IL231828A IL231828D0 (en) 2011-10-18 2014-03-31 Etanercept formolations stabilized with xylitol
IL231829A IL231829D0 (en) 2011-10-18 2014-03-31 Etanercept formulations stabilized with combinations of sugars and polyols
IL231826A IL231826D0 (en) 2011-10-18 2014-03-31 Etanercept formulations stabilized with sodium chloride
IL231827A IL231827D0 (en) 2011-10-18 2014-03-31 Etanercept formulations stabilized with meglumine
IL231824A IL231824D0 (en) 2011-10-18 2014-03-31 Etanercept formulations stabilized with amino acids
IL231825A IL231825D0 (en) 2011-10-18 2014-03-31 Etanercept formulations stabilized with metal ions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL231828A IL231828D0 (en) 2011-10-18 2014-03-31 Etanercept formolations stabilized with xylitol

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL231826A IL231826D0 (en) 2011-10-18 2014-03-31 Etanercept formulations stabilized with sodium chloride
IL231827A IL231827D0 (en) 2011-10-18 2014-03-31 Etanercept formulations stabilized with meglumine
IL231824A IL231824D0 (en) 2011-10-18 2014-03-31 Etanercept formulations stabilized with amino acids
IL231825A IL231825D0 (en) 2011-10-18 2014-03-31 Etanercept formulations stabilized with metal ions

Country Status (19)

Country Link
US (15) US9393305B2 (en)
EP (6) EP2768532A4 (en)
JP (6) JP6220788B2 (en)
KR (6) KR20140079491A (en)
CN (6) CN103998060B (en)
AR (6) AR088379A1 (en)
AU (6) AU2012326080B2 (en)
BR (6) BR112014009031A2 (en)
CA (6) CA2851635A1 (en)
DK (1) DK2768525T3 (en)
EA (6) EA027325B1 (en)
HK (6) HK1200720A1 (en)
IL (6) IL231828D0 (en)
IN (3) IN2014CN02527A (en)
LT (1) LT2768525T (en)
MX (6) MX2014004728A (en)
SG (6) SG11201401519RA (en)
TW (6) TWI619504B (en)
WO (6) WO2013059408A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012326080B2 (en) * 2011-10-18 2017-02-16 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
EP2869817A4 (en) * 2012-07-09 2016-04-06 Coherus Biosciences Inc Stable aqueous formulations of etanercept
ES2657377T3 (en) * 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept folded correctly with high purity and excellent performance
JP2016518386A (en) * 2013-05-02 2016-06-23 マブキシェンス エス.アー. Alternative formulation of TNFR: Fc fusion polypeptide
WO2015056613A1 (en) * 2013-10-15 2015-04-23 Meiji Seikaファルマ株式会社 Stabilized polypeptide aqueous preparation
RU2016119755A3 (en) * 2013-10-24 2018-04-28
CA2930227A1 (en) * 2013-11-29 2015-06-04 Ares Trading S.A. A liquid formulation of a fusion protein comprising tnfr and fc region
IS3008B (en) 2014-05-14 2018-12-15 Calor ehf A peptide or protein stabilizing formulation
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
JP2018501311A (en) * 2014-12-22 2018-01-18 アレス トレーディング ソシエテ アノニム Liquid pharmaceutical composition
US20180256717A1 (en) * 2014-12-23 2018-09-13 Drug Discovery Laboratory As Protein compositions and use thereof
WO2016108569A1 (en) * 2014-12-31 2016-07-07 주식회사 엘지생명과학 Method for producing tnfr-fc fusion protein containing target content of impurities
CN104694355B (en) * 2015-03-20 2016-09-28 吉林大学 Pueraria liver health wine and its preparation method
MX2015010517A (en) * 2015-08-13 2017-02-13 Landsteiner Scient S A De C V Etanercept composition having improved stability.
JP5938762B1 (en) * 2015-09-01 2016-06-22 日揮株式会社 Microcapsule preparation and production method thereof
CN105748414A (en) * 2016-03-02 2016-07-13 张光泉 Anti-infection micafungin freeze-drying composition and preparation method thereof
WO2017179683A1 (en) * 2016-04-15 2017-10-19 Meiji Seikaファルマ株式会社 Pharmaceutical composition containing micafungin in stabilized state
MX2017013995A (en) * 2017-10-31 2019-05-01 Probiomed S A De C V Stable pharmaceutical formulation of a fusion protein.

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (en) 1996-11-19 1998-07-15 Boehringer Mannheim Gmbh Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
AU4363200A (en) 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CN1406132A (en) 2000-02-10 2003-03-26 惠氏公司 Method for treating or inhibiting cellular injury or cell death
CA2444480C (en) * 2001-02-23 2014-05-27 Lucia Irene Gonzalez-Villasenor Methods and compositions for production of recombinant peptides
DK1478394T3 (en) 2002-02-27 2008-10-13 Immunex Corp Stabilized TNFR-Fc formulation with arginine
KR20050105486A (en) * 2003-02-28 2005-11-04 아레스 트레이딩 에스.에이. Liquid formulations of tumor necrosis factor-binding proteins
JPWO2004082715A1 (en) 2003-03-20 2006-06-22 エーザイ株式会社 A pharmaceutical combination as inflammatory bowel disease treatment agents
EP1654281A1 (en) 2003-08-01 2006-05-10 Amgen, Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
NZ546347A (en) 2003-10-14 2009-11-27 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
WO2005082377A1 (en) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. INHIBITOR FOR LOWERING IN THE ACTIVITY OF ANTIHUMAN TNF-α ANTIBODY
AU2005229359C1 (en) 2004-03-05 2011-07-28 Patheon Holdings I B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
CN101237890A (en) 2005-06-10 2008-08-06 中外制药株式会社 Stabilizer for protein preparation comprising meglumine and use thereof
CN101217979A (en) * 2005-06-14 2008-07-09 安姆根有限公司 Self-buffering protein formulations
AU2006330593B2 (en) 2005-12-20 2012-07-26 Bristol-Myers Squibb Company Stable protein formulations
JP5405122B2 (en) * 2005-12-21 2014-02-05 ワイス・エルエルシー Low viscosity protein formulations and uses thereof
MX2008011874A (en) * 2006-03-17 2009-01-07 Biogen Idec Inc Stabilized polypeptide compositions.
MX2008013535A (en) 2006-04-21 2008-10-29 Amgen Inc Buffering agents for biopharmaceutical formulations.
EP2059589A2 (en) * 2006-08-01 2009-05-20 Illumigen Biosciences Inc. Pharmaceutical manufacturing methods
WO2008045373A2 (en) * 2006-10-06 2008-04-17 Amgen Inc. Stable antibody formulations
TW200833357A (en) 2006-10-20 2008-08-16 Amgen Inc Stable polypeptide formulations
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
CA2672902C (en) * 2006-12-21 2012-11-27 Amgen Inc. Formulations
RU2009132986A (en) 2007-03-02 2011-04-10 Уайт (Us) The use of copper and glutamate in the cell culture for the production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
DK2170390T3 (en) * 2007-06-14 2019-01-21 Biogen Ma Inc Natalizumabantistofformuleringer
AU2008334099B2 (en) 2007-11-30 2014-07-24 Abbvie Biotechnology Ltd. Protein formulations and methods of making same
CN101969929B (en) * 2008-01-15 2014-07-30 Abbvie德国有限责任两合公司 Powdered protein compositions and methods of making same
MX2010009398A (en) 2008-02-29 2010-11-12 Biogen Idec Inc Purified immunoglobulin fusion proteins and methods of their purification.
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
CN102498206A (en) 2009-08-11 2012-06-13 弗·哈夫曼-拉罗切有限公司 Production of proteins in glutamine-free cell culture media
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
US20130052195A1 (en) * 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
DK2563904T3 (en) 2010-04-26 2015-04-07 Novartis Ag Improved cell culture medium
RU2600847C2 (en) * 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Liquid composition of polypeptides containing fc domain of immunoglobulin
US20130209465A1 (en) * 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
JP2013535981A (en) 2010-08-20 2013-09-19 ワイス・エルエルシー Cell culture of growth factor-free compatible cells
US20130224855A1 (en) 2010-08-31 2013-08-29 Abhishek Gupta Culture medium for eukaryotic cells
JP5996631B2 (en) * 2011-04-20 2016-09-21 サンド・アクチエンゲゼルシヤフト Stable pharmaceutical solution of TNFR: Fc fusion protein
UY34105A (en) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Etanercept stable liquid formulation
KR20180050433A (en) 2011-07-01 2018-05-14 암젠 인크 Mammalian cell culture
KR20140056218A (en) * 2011-07-01 2014-05-09 바이오겐 아이덱 엠에이 인코포레이티드 Arginine-free tnfr : fc- fusion polypeptide compositions and methods of use
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
AU2012326080B2 (en) * 2011-10-18 2017-02-16 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine

Also Published As

Publication number Publication date
KR20140091706A (en) 2014-07-22
EP2768535A4 (en) 2015-03-11
MX2014004732A (en) 2015-05-15
EA201490802A1 (en) 2014-08-29
AR088383A1 (en) 2014-05-28
US20190290768A1 (en) 2019-09-26
MX2014004734A (en) 2015-05-15
MX2014004725A (en) 2015-02-05
JP6104922B2 (en) 2017-03-29
KR20140083037A (en) 2014-07-03
EP2768525A4 (en) 2015-07-15
HK1200721A1 (en) 2015-08-14
US20130108633A1 (en) 2013-05-02
JP2014530254A (en) 2014-11-17
SG11201401563SA (en) 2014-09-26
JP6220788B2 (en) 2017-10-25
KR20140079491A (en) 2014-06-26
CA2851651A1 (en) 2013-04-25
WO2013059407A1 (en) 2013-04-25
BR112014009146A2 (en) 2017-06-13
EA201490815A1 (en) 2014-09-30
US20130101640A1 (en) 2013-04-25
TW201325611A (en) 2013-07-01
US9943601B2 (en) 2018-04-17
IL231827D0 (en) 2014-05-28
JP2014530862A (en) 2014-11-20
BR112014009073A2 (en) 2017-05-09
HK1200718A1 (en) 2015-08-14
EP2768535A1 (en) 2014-08-27
IL231824D0 (en) 2014-05-28
WO2013059408A1 (en) 2013-04-25
TWI644681B (en) 2018-12-21
EP2768854A4 (en) 2015-03-11
BR112014009146A8 (en) 2017-06-20
SG11201401562RA (en) 2014-09-26
US20190290767A1 (en) 2019-09-26
HK1200720A1 (en) 2015-08-14
US20130108632A1 (en) 2013-05-02
JP6220789B2 (en) 2017-10-25
SG11201401517VA (en) 2014-09-26
KR20140097184A (en) 2014-08-06
EA027325B1 (en) 2017-07-31
US20190216930A1 (en) 2019-07-18
EP2768531A4 (en) 2015-03-11
MX2014004728A (en) 2015-05-15
AR088380A1 (en) 2014-05-28
EA025663B1 (en) 2017-01-30
CN104010658A (en) 2014-08-27
MX2014004733A (en) 2015-05-15
EP2768525B1 (en) 2019-06-19
US9801942B2 (en) 2017-10-31
CN104011073B (en) 2017-08-25
US10376588B2 (en) 2019-08-13
AU2012326168B2 (en) 2016-12-15
EA201490803A1 (en) 2014-09-30
AU2012326170B2 (en) 2016-12-22
MX2014004726A (en) 2015-05-15
WO2013059412A1 (en) 2013-04-25
AR088379A1 (en) 2014-05-28
TW201325607A (en) 2013-07-01
HK1200851A1 (en) 2015-08-14
US20190290766A1 (en) 2019-09-26
JP2014530255A (en) 2014-11-17
TW201325606A (en) 2013-07-01
AU2012326171A1 (en) 2014-04-24
AR088381A1 (en) 2014-05-28
KR20140091707A (en) 2014-07-22
EP2768854A1 (en) 2014-08-27
IN2014CN02592A (en) 2015-09-04
CN103998060B (en) 2016-12-21
EP2768533A1 (en) 2014-08-27
US20180125982A1 (en) 2018-05-10
EA025267B1 (en) 2016-12-30
EP2768533A4 (en) 2015-03-11
EA201490801A1 (en) 2014-09-30
CN103998060A (en) 2014-08-20
US20160199489A1 (en) 2016-07-14
TW201325609A (en) 2013-07-01
JP2014530864A (en) 2014-11-20
BR112014009031A2 (en) 2017-05-09
JP6199298B2 (en) 2017-09-20
SG11201401519RA (en) 2014-07-30
AU2012326080A1 (en) 2014-04-24
EP2768531A1 (en) 2014-08-27
CN104011073A (en) 2014-08-27
LT2768525T (en) 2019-09-25
SG11201401567YA (en) 2014-07-30
AU2012326171B2 (en) 2017-03-09
JP6113176B2 (en) 2017-04-12
US20180193463A1 (en) 2018-07-12
CN104010654A (en) 2014-08-27
US10213508B2 (en) 2019-02-26
AU2012326080B2 (en) 2017-02-16
EA028520B1 (en) 2017-11-30
IL231828D0 (en) 2014-05-28
AU2012326084B2 (en) 2016-12-15
BR112014009131A8 (en) 2017-06-20
US9393305B2 (en) 2016-07-19
AR088460A1 (en) 2014-06-11
US9770510B2 (en) 2017-09-26
AU2012326084A1 (en) 2014-04-17
BR112014009131A2 (en) 2017-06-13
CA2851635A1 (en) 2013-04-25
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (en) 2015-06-26
CN103998061A (en) 2014-08-20
TW201325610A (en) 2013-07-01
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
JP2014530863A (en) 2014-11-20
TW201325608A (en) 2013-07-01
EA201490804A1 (en) 2014-09-30
JP2014530256A (en) 2014-11-17
IN2014CN02527A (en) 2015-06-26
WO2013059405A1 (en) 2013-04-25
CA2851646A1 (en) 2013-04-25
HK1200722A1 (en) 2015-08-14
JP6110393B2 (en) 2017-04-05
TWI595883B (en) 2017-08-21
US9302002B2 (en) 2016-04-05
EP2768525A1 (en) 2014-08-27
CN104010657A (en) 2014-08-27
US20130101584A1 (en) 2013-04-25
US20190184017A1 (en) 2019-06-20
AU2012326082A1 (en) 2014-04-24
IL231826D0 (en) 2014-05-28
CA2851642A1 (en) 2013-04-25
BR112014009022A2 (en) 2017-05-02
EA026410B1 (en) 2017-04-28
US20190290765A1 (en) 2019-09-26
CN104010654B (en) 2017-10-27
US20160317667A1 (en) 2016-11-03
EA201490817A1 (en) 2014-09-30
SG11201401576WA (en) 2014-10-30
CA2851628A1 (en) 2013-04-25
AR088382A1 (en) 2014-05-28
AU2012326168A1 (en) 2014-04-24
WO2013059406A1 (en) 2013-04-25
DK2768525T3 (en) 2019-07-22
EP2768532A4 (en) 2015-03-11
AU2012326170A1 (en) 2014-04-24
TWI619504B (en) 2018-04-01
IL231825D0 (en) 2014-05-28
EP2768532A1 (en) 2014-08-27
US10293049B2 (en) 2019-05-21
AU2012326082B2 (en) 2016-12-15
BR112014009087A2 (en) 2017-04-18
KR20140091705A (en) 2014-07-22
CA2851639A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
GB2516540B (en) Protective case and methods of making
TWM421896U (en) Improved structure of chair
IL232257D0 (en) Personal aircraft
IL265707D0 (en) Pharmaceutical compositions comprising human antibodies to pcsk9
ZA201400678B (en) Alpha-amylase variants
HRP20190135T1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
AP201407499A0 (en) Antibodies to PCSK9 and uses thereof
ZA201401801B (en) Pest control formulations and methods of making and using same
PL2591114T3 (en) Immunisation of large mammals with low doses of rna
HK1188194A1 (en) Beverage delivery pod and methods of use and manufacture
EP2721019A4 (en) Therapeutically active compositions and their methods of use
ZA201309060B (en) Synthetic formulations and methods of manufacturing and using thereof
EP2694095A4 (en) Compositions comprising glucagon analogs and methods of making and using the same
SG10201602752XA (en) Melanin modification compositions and methods of use
EP2635690A4 (en) Compositions and methods for production of fermentable sugars
EP2667915A4 (en) Injector
HK1202071A1 (en) Biocidal compositions and methods of using the same
BR112013023776A2 (en) composition and seal-sealed opening
IL228721A (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines and pharmaceutical compositions thereof
IL229431D0 (en) Anti-cgrp composition and use thereof
IL231825D0 (en) Etanercept formulations stabilized with metal ions
EP2739144A4 (en) Compounds and therapeutic uses thereof
EP2714180A4 (en) Catheter with stepped skived hypotube
EP2774933A4 (en) Ulipristal acetate preparation method and intermediate thereof
AP3519A (en) Use of fluopyram for controlling nematodes in crops and for increasing yield